The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Volrustomig, a novel bispecific PD-1/CTLA-4 monoclonal antibody, as single-agent first-line therapy for unresectable pleural mesothelioma: Substudy 5 of the eVOLVE-02 phase 2 study.
 
Michael Offin
Honoraria - OncLive
Consulting or Advisory Role - American Society for Radiation Oncology; Jazz Pharmaceuticals; Novartis; Pfizer; PharmaMar; SERVIER; Targeted Oncology; Vivace Therapeutics
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
(OPTIONAL) Uncompensated Relationships - Mesothelioma Applied Research Foundation
 
Xiaoling Zeng
Employment - AstraZeneca
Leadership - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Honoraria - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Shenqi Wang
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Bingying Xie
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Melina Marmarelis
Stock and Other Ownership Interests - Johnson & Johnson; Merck
Honoraria - Janssen Oncology; Takeda
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/Astra Zeneca; Janssen Oncology; NEUVOGEN
Research Funding - AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Regeneron